Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.
This study wants to assess different intensive therapy sequences for the treatment of non-small-cell lung cancer.
It claims less on the efficacy of different chemotherapy combinations, than more on the comparison of different strategies of sequential single-agent, sequential double-agent or sequential triple-agent therapy.
|Non-Small-Cell Lung Carcinoma||Drug: Gemcitabine Drug: Navelbine Drug: Carboplatin Drug: Cisplatin Drug: Mitomycin Drug: Ifosfamide||Phase 3|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00148395
|Klinikum Kassel GmbH|
|Kassel, Germany, 34125|
|Study Chair:||Martin Wolf, MD||Klinikum Kassel GmbH|